Study: A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AL001 in Individuals at Risk for or With Frontotemporal Dementia Due to Heterozygous Mutations in the Progranulin Gene
Please Select Your Affiliation with CU Anschutz
Thank you for expressing your interest in a research study and for taking the time to provide your information.
By clicking 'Submit', your information will be shared with the research team. Typically a member of the research team will contact you within 1 to 2 business days. Due to the current situation related to the coronavirus (COVID-19), members of the research team may experience delays in contacting you regarding your interest in participating. A member of the research team will respond to you as soon as possible.
Please understand that:
- The research team will need to determine whether you are eligible for the study. Clicking 'Submit' does not enroll you into the study, or guarantee that you qualify for the study.
- It is always your choice to participate.
Thanks again. Volunteers such as yourself are at the core of our work.